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ABSTRACT Therapies for human African trypanosomiasis and Chagas disease, caused
by Trypanosoma brucei and Trypanosoma cruzi, respectively, are limited, providing
minimal therapeutic options for the millions of individuals living in very poor com-
munities. Here the effects of 10 novel quinolines are evaluated in silico and by phe-
notypic studies using in vitro and in vivo models. Absorption, distribution, metabo-
lism, excretion, and toxicity (ADMET) properties revealed that most molecules did
not infringe on Lipinski’s rules, which is a prediction of good oral absorption. These
quinolines showed high probabilities of Caco2 permeability and human intestinal
absorption and low probabilities of mutagenicity and of hERG1 inhibition. In vitro
screens against bloodstream forms of T. cruzi demonstrated that all quinolines were
more active than the reference drug (benznidazole [Bz]), except for DB2171 and
DB2192, with ﬁve (DB2187, DB2131, DB2186, DB2191, and DB2217) displaying 50%
effective concentrations (EC50s) of 3 M (4-fold lower than that of Bz). Nine quino-
lines were more effective than Bz (2.7 M) against amastigotes, showing EC50s rang-
ing from 0.6 to 0.1 M. All quinolines were also highly active in vitro against African
trypanosomes, showing EC50s of 0.25 M. The most potent and highly selective
candidates for each parasite species were tested in in vivo models. Results for
DB2186 were promising in mice with T. cruzi and T. brucei infections, reaching a 70%
reduction of the parasitemia load for T. cruzi, and it cured 2 out of 4 mice infected
with T. brucei. DB2217 was also active in vivo and cured all 4 mice (100% cure rate)
with T. brucei infection.
KEYWORDS Trypanosoma cruzi, Trypanosoma brucei, experimental chemotherapy,
quinolines, in vitro, in vivo, in silico
Currently, more than 1 billion people live in poverty, without access to basicsanitation, favoring the emergence and development of various diseases. The WHO
grouped 20 pathologies caused by viruses, fungi, bacteria, protozoans, and helminths,
named neglected tropical diseases, that have a severe impact in on public health
programs of developing countries but present low interest and investments for the
development of early diagnostic tools and safer/potent therapies by most pharmaceu-
tical companies (https://www.dndi.org/) (1, 2).
Human African trypanosomiasis (HAT), or sleeping sickness, is a lethal disease in
sub-Saharan Africa caused by two subspecies of Trypanosoma brucei: Trypanosoma
brucei gambiense is endemic in western and central Africa, and Trypanosoma brucei
rhodesiense is most prevalent in eastern and southern Africa (3). Both parasite subspe-
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cies are transmitted by the bite of an infected tsetse ﬂy (genus Glossina). Clinical
presentations vary according to the subspecies and the disease stage. The symptoms
of the hemolymphatic stage are mostly nonspeciﬁc and include fever, headache, and
swelling of the lymph nodes. In the second, meningoencephalitic stage, the trypomas-
tigotes infect the central nervous system in addition to the blood and lymph system.
Neurological symptoms such as mental confusion and emotional lability as well as
convulsions and alteration of the circadian rhythm, a characteristic giving the disease
its name, accompany the second stage. Sleeping sickness is fatal, if left untreated (3).
Chagas disease (CD), also a neglected tropical disease, is endemic in 21 countries in
Latin America, constituting a continuing serious public health problem and presenting
a chronic progressive pathology that affects more than 6 million to 8 million people
worldwide (https://www.dndi.org/). CD is caused by the protozoan Trypanosoma cruzi,
and its transmission occurs primarily via bug triatomine vectors and may also include
other routes such as blood transfusion, congenital transmission (both of which are
declining due to public health measures adopted by countries where the disease is
endemic), laboratory accidents, and ingestion of food and drinks contaminated with
the feces of and/or entire triatomines containing infective forms of the parasite (4).
Current treatment of CD is based on two nitroheterocyclic drugs, nifurtimox (Nif) and
the 2-nitroimidazole benznidazole (Bz), introduced into clinical therapy over 5 decades
ago (5). Recent clinical trials (6, 7) performed on chronically infected patients to
evaluate the azole inhibitors of CYP51 (prodrug of ravuconazole and posaconazole) and
a nitroderivative (fexinidazole) showed high rates of therapeutic failure despite their
excellent activity in vitro and in vivo using experimental models (mouse and canine
models), arguing for the generation of more predictive in vitro and in vivo data (5, 8, 9).
For HAT, a total of ﬁve drugs are available. However, treatment recommendations
fall back to one option for each subspecies and disease stage. Pentamidine (T. b.
gambiense) and suramin (T. b. rhodesiense) are used as ﬁrst-line treatments for ﬁrst-
stage disease, and melarsoprol (T. b. rhodesiense) and a combination of eﬂornithine and
nifurtimox (T. b. gambiense) are used for second-stage disease (1). The main general
limitations of the current therapies for both HAT and CD include considerable adverse
effects, high costs, the requirement for long periods of exposure, the occurrence of
natural and acquired resistant parasites, and treatment failures, especially in the later
pathological stages (9). These ﬁndings underscore the urgent need to search for new
trypanocidal agents with characteristics for each target product proﬁle (for CD and
HAT) (https://www.dndi.org/) (4, 10). In this context, many compounds have been
tested in vitro and in vivo, but until now, only a few candidates have been found (5,
11–13).
The present work with quinolines is based on a high-throughput phenotypic
screening of a library of 700,000 compounds by the Genomics Institute of the Novartis
Research Foundation. It yielded over a hundred different scaffolds that were nontoxic
to human cells and were active (3.6 M or lower) against T. brucei (14). One of the initial
hits, 2-(2-benzamido)ethyl-4-phenylthiazole, has been extensively explored, and a num-
ber of compounds that were highly active against T. brucei in vitro were discovered (15).
However, these compounds were only moderately effective in the STIB900 mouse
model of T. b. rhodesiense infections, which was attributed, at least in part, to poor
metabolic stability (15). We undertook an exploration of N-(2-phenylquinolin-7-
yl)benzamides and related compounds, which retain similar geometric relationships
between the amide unit and the thiazole nitrogen atom hypothesized to be important
for activity. In this quinoline system, the “ethylamine link” of the original thiazole hit is
incorporated into the quinoline ring and may improve metabolic stability. While our
study was in progress, excellent in vivo results against both early- and late-stage T.
brucei infections in mice for a benzothiazole analogue of the initial hit were reported
by that same group (15).
Thus, in this work, we investigate the phenotypic activities of 10 novel quinolines
through whole-cell-based assays in vitro by assaying different parasite forms (trypo-
mastigotes and amastigotes) and strains (discrete typing unit [DTU] II and VI) of T. cruzi
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in addition to exploring their biological activities against bloodstream forms of T. b.
rhodesiense in vitro. Furthermore, the toxicity proﬁles of these quinolines were studied
by using different mammalian cells and by their predictive pharmacological properties
evaluated by pKCSM. Finally, the most promising compounds were moved to animal
models of T. b. rhodesiense and T. cruzi infections, with the aim to contribute to the
identiﬁcation of novel therapeutic options for these severe neglected pathologies.
RESULTS
A phenotypic in vitro study using the 10 quinoline derivates (Table 1) was performed on
T. cruzi and T. brucei parasites. Considering that all active drug candidates for T. cruzi must
also be assessed against the relevant intracellular forms (16), the initial step consisted of
analyses of intracellular forms (Tulahuen strain transfected with -galactosidase [DTU VI]
and Y strain [DTU II]). Our ﬁndings for the Tulahuen strain showed that all quinolines
were more potent than Bz when infected L929 cells were incubated for 96 h at 37°C,
with 50% effective concentrations (EC50s) ranging from 0.1 M up to 2.05 M and
selectivity indices (SI) ranging from 48 up to 960 (Table 1). By screening against
intracellular forms of the Y strain lodged inside cardiac cells (CC), the trypanocidal
efﬁcacy of quinolines was conﬁrmed, as DB2187 exhibited a low EC50 (1.03 0.3 M)
(data not shown).
Following 24 h of incubation with trypomastigote forms of T. cruzi (Y strain [DTU II]),
except for DB2171 and DB2192, all quinolines presented higher trypanocidal activity
than that of Bz, exhibiting EC50s of 8 M (Table 1). Among these quinolines, DB2187
and its analogue DB2186 were the most effective (EC50 of 0.8 M), being about
12-fold more potent than the reference drug. All molecules also showed high trypano-
cidal activity against T. brucei bloodstream forms, with EC50s ranging from 0.016 to
0.239 M, and strong selectivity for this parasite, with selectivity indices ranging from
88 to 5,455 (Table 1). The cytotoxicity data for the studied quinolines using colorimetric
assays with PrestoBlue (cardiac cells) and alamarBlue (L929 cultures) showed that all
molecules were tolerated, with no detectable toxicity at concentrations of up to 96 M
after 24 to 96 h of incubation (data not shown). The lack of mammalian host toxicity
was conﬁrmed when DB2104, DB2131, DB2161, DB2171, and DB2191 were tested (up
to 48 h) using higher concentrations on cardiac cells (up 400 M) (data not shown).
Cytotoxicity against L6 cells was also low and varied from 15 M (DB2217) to270 M
(DB2187). Fifty percent lethal concentrations (LC50s) of each compound on L6 cells can
be deduced from the SI of T. b. rhodesiense (Table 1).
For both parasite species (T. brucei and T. cruzi), DB2186 was the most potent
molecule from this series, without inhibiting mammalian cells. Absorption, distribution,
metabolism, excretion, and toxicity (ADMET) properties of quinolines predicted by
using the pKCSM tool revealed that DB2186, DB2187, DB2192, and DB2217 did not
infringe on Lipinski’s rule of ﬁve, which is a prediction of good oral absorption (Table
2). The quinolines showed a good probability of permeability on Caco2 cells, with
values above the adopted threshold of 0.9; probabilities of human intestinal absorption
of 89%, with an even better oral absorption proﬁle than that of Bz; and a positive
prediction to be metabolized by CYP3A4 (Table 3). These quinolines have a low
probability of mutagenicity and no prediction to inhibit hERG1, although they all show
the possibility of inhibiting hERG2 and a hepatotoxicity proﬁle similar to that of Bz
(Table 4). Evaluation of hepatic markers in biochemical analyses in vivo using mouse
models of acute toxicity demonstrated no alterations of the plasma levels of alanine
aminotransferase (ALT) (except for DB2192), aspartate aminotransferase (AST), urea,
and creatine kinase (CK) in addition to no major clinical signs (except for losses of
animal weight) when mice were given up to 200 mg/kg of body weight of DB2187 and
its derivatives DB2186, DB2191, and DB2192 and monitored up to 48 h (data not
shown). Next, based on the excellent phenotypic ﬁndings and lack of preliminary acute
toxicity indications, DB2187 and derivatives were moved to in vivo antiparasitic anal-
yses using mouse models.
Male mice inoculated with 104 bloodstream forms (T. cruzi Y strain) and treated
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TABLE 1 Antitrypanosomal activities of novel quinolines against bloodstream trypomastigotes of T. brucei and intracellular and
bloodstream forms of T. cruzi and corresponding selective indicesa
Chemical structure Compound
Mean EC50 (M)  SD (SI value)
T. b. rhodesiense
BT forms
T. cruzi
BT forms Intracellular forms
Pentamidine 0.003 (11.4368) NT NT
Melarsoprol 0.004 (1.275) NT NT
Benznidazole NT 9.6 1.4 (104) 2.7 1 (370)
DB2104 0.213 (971) 6.1 2.8** (66) 0.54 0.2 (178)
DB2131 0.204 (229) 2.5 1.1** (160) 0.6 0.3 (160)
DB2161 0.076 (1.164) 8 2.9 (50) 0.5 0.038 (192)
DB2171 0.239 (983) 15 8 (27) 2.05 0.6 (47)
DB2186 0.016 (1.761) 0.78 0.46** (123) 0.15 0.01 (640)
DB2187 0.050 (5.455) 0.8 0.2** (137) 0.36 0.12 (233)
DB2191 0.057 (647) 2.6 0.64** (154) 0.1 0 (960)
(Continued on next page)
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(intraperitoneally [i.p.]) at 5 and 8 days postinfection (dpi) using nontoxic concentra-
tions of DB2187 gave a maximum reduction of parasitemia of 38% at the peak (8 dpi)
in comparison to the vehicle group but failed to protect against mortality induced by
parasite infection (Table 5). The administration of nontoxic concentrations of DB2186,
DB2191, and DB2192 at 25 mg/kg/day for ﬁve consecutive days in T. cruzi-infected male
and female mice showed that DB2186 was the most active compound, reaching 25 and
70% reductions of the blood parasitemia loads, respectively, when 25 mg/kg was given
for ﬁve consecutive days, while Bz completely suppressed parasitism (Table 5). Regard-
ing the effects on mortality induced by experimental T. cruzi infection, infected female
and male mice treated with the vehicle only displayed 50 and 17% survival rates,
respectively, whereas all the Bz-treated animals were alive. The tested quinolines were
not able to provide signiﬁcant protection against mortality (Table 5).
The quinolines were also evaluated for their antitrypanosomal efﬁcacy in T. b.
rhodesiense-infected mice. In the preliminary experiment, the compounds were tested
on small groups of 2 mice treated at 40 mg/kg/day i.p. for three consecutive days. Six
compounds showed activity on the level of a strong reduction of parasitemia (98%)
in at least one of the two mice and were well tolerated at the tested dosage (Table 6).
These compounds were further tested in 4 infected mice at a higher dosage of 50
mg/kg/day i.p. for four consecutive days. DB2186 and DB2217 were the best molecules
and cured 2 of 4 infected mice and all 4 infected mice, respectively (Table 6).
TABLE 1 (Continued)
Chemical structure Compound
Mean EC50 (M)  SD (SI value)
T. b. rhodesiense
BT forms
T. cruzi
BT forms Intracellular forms
DB2192 0.045 (3.828) 24 5.8 (4) 0.1 0.001 (960)
DB2212 0.123 (2.118) 7.2 3.2 (12) 0.3 0.039 (320)
DB2217 0.170 (88) 2.7 1.2** (36) 0.41 0.27 (234)
a**, P  0.05 as determined by ANOVA of the studied compound and Bz; SI, selectivity index; NT, not tested.
TABLE 2 Physicochemical parameters and Lipinski’s rule of ﬁvea
Compound
Water solubility
(mg/liter)
No. of
donors
No. of
acceptors LogP MW
DB2104 2.394 2 4 5.154 324.383
DB2131 1.041 2 4 5.293 342.373
DB2161 1.416 3 4 5.215 330.412
DB2171 2.775 2 4 5.030 316.404
DB2186 3.887 2 4 4.529 317.392
DB2187 5.9 1 2 4.9 333.419
DB2191 1.416 3 4 5.215 330.412
DB2192 5.356 2 4 4.305 315.376
DB2212 0.934 2 4 5.309 345.446
DB2217 2.587 2 4 4.695 329.403
Bz 376.248 1 5 0.11 260.253
aMW, molecular weight; LogP, partition coefﬁcient.
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DISCUSSION
Most drug development programs for neglected diseases are time-consuming
(often more than 10 years) and highly expensive (more than $1 billion) and get only
limited attention by the pharmaceutical industry. Until now, no vaccine has been
available for Chagas disease and for HAT, and the current therapies available have
strong liabilities; thus, novel therapeutic options are urgently needed. Drug discovery
and development strategies include phenotypic screening of synthetic and natural
molecules, assessment of combination therapies, repurposing of medicines, and drug
development toward selective parasite targets (11, 17, 18). Our goal was to investigate
the biological effects in vitro and in vivo of the 10 novel quinoline derivatives (Table 1)
on T. cruzi and T. brucei infections. We conducted different analyses that included
computational and cell-based screening as well as mouse models of trypanosome
infections. As reported previously, in silico analyses have the advantages of low cost,
fast processing, and the fact that compounds can be evaluated without synthesizing
them, allowing large libraries to be explored (22). However, computational screens
TABLE 3 In silico ADMEa
Parameter
Value for compound
DB2104 DB2131 DB2161 DB2171 DB2186 DB2187 DB2191 DB2192 DB2212 DB2217 Bz
Absorption
Caco2 cell permeability (log cm/s) 1.491 1.163 1.773 1.765 1.373 1.21 1.773 1.361 1.158 1.384 0.479
Intestinal absorption (human) (%) 94.747 89.969 89.46 90.659 90.877 91.515 89.46 91.353 90.1 90.964 68.885
Skin permeability (logKp) 2.763 3.167 3.118 3.092 3.214 3.012 3.118 3.238 3.198 3.23 2.893
Distribution
Vss (human) (liters/kg) 0.345 5.521 5.140 6.124 4.721 0.115 5.140 4.624 5.508 4.989 0.787
Fraction unbound (human) 0 0.278 0.292 0.3 0.321 0.064 0.292 0.331 0.275 0.307 0.503
BBB permeability 0.264 0.265 0.241 0.254 0.201 0.269 0.241 0.2 0.227 0.213 0.619
CNS permeability 1.013 2.778 2.687 2.687 2.691 1.639 2.687 2.691 2.782 2.737 2.995
Metabolism
CYP2D6 substrate No No No No No No No No No No No
CYP3A4 substrate Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
CYP1A2 inhibitor Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
CYP2C19 inhibitor Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
CYP2C9 inhibitor Yes No No No No No No No No No No
CYP2D6 inhibitor No No No No No No No No No No No
CYP3A4 inhibitor No No No No No No No No No No No
Excretion
Total clearance (ml/min/kg) 3.793 6.998 12.023 10.162 8.433 0.545 12.023 6.714 6.823 6.368 4.217
aVss, volume of distribution at steady state; BBB, blood-brain barrier; CNS, central nervous system; logKp, skin permeability constant (cm/h).
TABLE 4 In silico toxicitya
Parameter
Value for compound
DB2104 DB2131 DB2161 DB2171 DB2186 DB2187 DB2191 DB2192 DB2212 DB2217 Bz
AMES toxicity No No No No No No No No No No Yes
Max tolerated dose (human)
(mol/kg)
17.418 1.393 1.758 1.807 1.758 0.784 1.758 1.766 1.330 1.535 9.638
hERG1 inhibitor I No No No No No No No No No No No
hERG2 inhibitor Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
Oral rat acute toxicity (LD50)
(mol kg1)
2.535 2.906 2.924 2.719 2.817 2.856 2.924 2.783 2.885 2.819 2.454
Oral rat chronic toxicity (LOAEL)
(mg/kg of body wt/day)
289.068 46.345 61.094 80.168 47.973 1.878 61.094 43.451 46.345 42.756 44.566
Hepatotoxicity Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Skin sensitization No No No No No No No No No No No
Tetrahymena pyriformis toxicity
(pIGC50 [g/liter])
5.929 29.923 33.884 31.405 31.842 1.256 33.884 31.333 28.642 30.479 16.866
Minnow toxicity (LC50 [mM]) 0.586 4.732 3.365 4.325 6.039 0.739 3.365 7.244 3.524 5.534 44.566
aLD50, 50% lethal dose; LOAEL, lowest observed adverse effect level; pIGC50, negative logarithm of the concentration required to inhibit 50% growth (in log g/liter).
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often fail to simulate the full complexity of biological systems and need to be com-
plemented with experimental studies (19). Here, the antiparasitic activities of the novel
quinolines were explored, considering different aspects of the drug discovery cascade
performed in in silico, in vitro (whole-cell-based), and in vivo (the most biologically
realistic) assays, according to current strategies for hit and lead identiﬁcation for novel
anti-T. cruzi and anti-T. brucei drugs. Our ﬁndings demonstrated the promising in vitro
activities of these compounds against both bloodstream trypomastigotes (T. cruzi and
T. brucei) and intracellular forms (T. cruzi) of these parasites, with most molecules
exhibiting greater potency than the reference drug for Chagas disease (Bz). The
quinolines also have the potential to be developed for T. brucei, although they were less
potent than the highly toxic compound melarsoprol or the T. b. gambiense ﬁrst-stage
drug pentamidine. The quinoline DB2186 was very active against both trypanosome
species regardless of the parasite form, displaying quite high selectivity indices that
were even superior to those reported previously for novel hits for CD and HAT (11, 12,
20). Regarding T. cruzi screens, the quinolines were active against parasite strains from
different DTUs (DTUs II and VI for the Y and Tulahuen strains, respectively), furthermore
showing low toxicity toward mammalian host cells, including primary cultures of
cardiac cells that provide, in a more sensitive manner, the potential for in vivo
cardiotoxicity. These are very critical data since the heart represents an important target
for T. cruzi infection and inﬂammation (21). In fact, plasma biochemical analyses of
quinoline-treated mice conﬁrmed the low-cardiotoxicity proﬁle determined by CK
measurements. Thus, in vitro whole-cell-based screening associated with theoretical
analyses of the ADMET properties and mouse models of acute toxicity were used to
select potential drug candidates to proceed to in vivo efﬁcacy evaluations (22). The in
silico properties of the novel quinolines were evaluated by using the pKCSM tool, and
the overall ﬁndings predicted good oral absorption, a high probability of permeability
in Caco2 cells, good human intestinal absorption, and low probabilities of mutagenicity
and inhibition of hERG1. The preliminary acute murine toxicity assays failed to dem-
onstrate increased levels of hepatic lesion markers such as ALT and AST, except for
DB2192 (statistically signiﬁcant enhancement of ALT levels, indicative of hepatic dam-
age). To evaluate efﬁcacy in vivo against T. cruzi infection, both female and male mouse
models were used, and our data conﬁrmed the higher susceptibility of male mice to T.
cruzi experimental infection than of female mice (25). The ﬁndings also demonstrated
that DB2186 was the most promising candidate for T. cruzi infection as well as for T.
brucei infection in murine models. It is important to consider that DB2186 exhibited
consistently high selectivity indices for T. cruzi (123 and 640 for bloodstream trypo-
TABLE 5 Antitrypanosomal activities of quinolines in mouse models of T. cruzi infection (Y
strain) using 25 mg/kg (i.p.) for ﬁve consecutive days starting at parasitemia onset (5 dpi)
Compound Mouse gender
% parasite variation at
parasitemia peak (8 dpi)
% cumulative mortality
at 30 days posttherapy
Benznidazolea Female 100 0
Male 100 0
Vehicle Female 0 50
Male 0 83
DB2187b Male 38 100
DB2186 Female 25 75
Male 70 50
DB2191 Female 9 50
Male 27 100
DB2192 Female 74 33
Male 28 100
aBenznidazole was tested at 100 mg/kg p.o.
bDB2187 was tested at 20 mg/kg i.p. at 5 and 8 dpi.
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mastigote [BT] and intracellular forms) and T. brucei (1,761 for BT). It is interesting to
note that DB2171 is much less active than two close analogues, DB2186 and DB2192,
pointing to the importance of the urea fragment for activity compared to the simple
amide unit.
The limited water solubility of the quinolines may have impaired a more successful
in vivo result, which also was not improved by the use of other vehicles, including
cyclodextrin and carboxymethylcellulose (data not shown). It is possible that minor
structural modiﬁcations can improve their solubility, allowing further animal studies.
The present set of results provides a basis for the development of novel quinoline
derivatives, following medicinal chemistry approaches, presenting better solubility and
improved potency, thus contributing to the identiﬁcation of more effective and safe
medicines to treat neglected tropical diseases such as Chagas disease and HAT.
MATERIALS AND METHODS
Compounds. The synthesis and characterization of the 10 quinolines (Table 1) can be found in the
supplemental material. For T. cruzi assays, Bz (2-nitroimidazole; Laboratório Farmacêutico do Estado de
Pernambuco [LAFEPE], Brazil) was used as a reference drug, and stock solutions were prepared in
dimethyl sulfoxide (DMSO), with the ﬁnal concentrations of the solvent never exceeding 0.6% and 10%
in assays in vitro and in vivo, respectively, which are not toxic to the parasite, mammalian cells, and mice.
For T. b. rhodesiense, pentamidine and melarsoprol were used as reference drugs. Pentamidine (Sigma)
was dissolved in DMSO, and melarsoprol (Arsobal; Aventis) was dissolved in water.
TABLE 6 Antitrypanosomal activities of quinolines in a mouse model of T. b. rhodesiense
STIB900 infection
Compound
% parasite reduction after
treatment with 3 doses of
40 mg/kg i.p.
No. of mice cured
with 4 doses of
50 mg/kg i.p./no.
of mice testedb1 day 3 days
Pentamidinea 100 100 4/4a
100 100
DB2104 98 98 NT
98 98
DB2131 98 100 0/4
98 98
DB2161 98 100 0/4
98 98
DB2171 98 99 0/4
98 98
DB2186 100 98 2/4
100 98
DB2187 98 100 0/4
98 98
DB2191 98 98 NT
98 98
DB2192 98 98 NT
98 98
DB2212 98 98 NT
98 98
DB2217 98 98 4/4
98 100
aPentamidine was tested at 3 doses of 4 mg/kg i.p. and at 4 doses of 1 mg/kg i.p. and cured all infected
mice.
bNT, not tested.
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Computational assessment of drug-like properties. Absorption, distribution, metabolism, excre-
tion, and toxicity (ADMET and Lipinski’s rule of ﬁve) properties of the studied quinolines were evaluated
by using the pKCSM approach, which uses graph-based signatures to develop predictive ADMET (22, 24).
Parasites. (i) T. cruzi. BT forms of the Y strain were obtained from blood samples of infected albino
Swiss mice at the peak of parasitemia. The puriﬁed parasites were resuspended in Dulbecco’s modiﬁed
Eagle medium (DMEM) supplemented with 10% fetal bovine serum as reported previously (25, 26).
Trypomastigotes of the Tulahuen strain expressing the Escherichia coli -galactosidase gene were
collected from the supernatant of T. cruzi-infected L929 cultures as reported previously (16, 27).
(ii) T. brucei. T. b. rhodesiense strain STIB900, a derivative of strain STIB704, was isolated from a
patient in Ifakara, Tanzania, in 1982 (28). Bloodstream forms were used for in vitro screening as well as
for the acute mouse infection model, which mimics the ﬁrst stage of HAT.
Mammalian cell cultures. For toxicity assays on mammalian cells, primary cultures of cardiac cells
(CC) obtained from mouse embryos were plated onto 96-well plates previously coated with 0.01% gelatin
(25). L929 cell lineages were obtained as described previously by Romanha et al. (16). L6 cells (rat skeletal
myoblast; ATCC CRL-1458) were maintained in RPMI 1640 medium supplemented with 2 mM
L-glutamine, 5.95 g/liter HEPES, 2 g/liter NaHCO3, and 10% fetal bovine serum at 37°C in a humidiﬁed
atmosphere containing 5% CO2 (29).
In vitro cytotoxicity tests. CC were incubated for 24 h at 37°C with different concentrations of each
compound (up to 400 M) diluted in DMEM; the morphology, cell density, and spontaneous contract-
ibility were then evaluated by light microscopy; and cellular viability was determined by the PrestoBlue
test as reported previously (27). L929 cells were incubated for 96 h at 37°C with different concentrations
of each compound (up to 96 M) diluted in RPMI, and cellular viability was determined by the alamarBlue
test as reported previously (27). The results were expressed according to the manufacturer’s instructions,
and the LC50 value, which corresponds to the concentration that reduces cellular viability by 50%, was
determined. Cytotoxicity assays performed by using L6 cells were conducted with a 72-h compound
exposure time as previously reported (29). The selectivity index (SI) was expressed as the ratio between
the LC50 values obtained on host or L6 cells and the EC50 obtained for the parasites.
Trypanocidal activity. For T. cruzi assays, BT of the Y strain (DTU II) (30) (5  106 BT per ml) were
incubated for 2 and 24 h at 37°C in RPMI in the presence or absence of serial dilutions of the compounds
(up to 32 M). After compound incubation, the death rates of parasites were determined by light
microscopy through the direct quantiﬁcation of the number of live parasites by using a Neubauer
chamber, and the EC50 (the compound concentration that reduces the number of parasites by 50%) was
calculated (22). For assaying intracellular forms of the Y strain (DTU II), the most promising compound
was further evaluated with infection of primary cultures of CC (using a ratio of 10 BT to 1 host cell). After
24 h of parasite interaction, the cultures were rinsed and incubated with the compounds for 48 h. After
ﬁxation with Bouin solution and staining with Giemsa solution, the percentage of CC infection and the
mean number of parasites per infected cell were calculated by light microscopy for the determination of
EC50s of the infection index (II) (II  % infected host cells  mean number of parasites per cell) (26).
Culture-derived trypomastigotes of T. cruzi (Tulahuen strain expressing -galactosidase [DTU VI]) were
used to infect L929 cultures at a ratio of 10:1 (parasites/host cell). After 2 h, the cultures were washed and
cultivated for another 48 h for the establishment of infection. The compounds were then added at
increasing nontoxic concentrations to mammalian host cells, followed by maintenance at 37°C for 96 h
for the determination of EC50s. After the addition of 50 l of the substrate (CPRG [chlorophenol red
glycoside] at 500 mM) in 0.5% Nonidet P40 and incubation at 37°C for 18 h, the absorbance at 570 nm
was measured, and results were expressed as percent inhibition of the infection rate (16). For T. brucei
assays, bloodstream forms of T. b. rhodesiense strain STIB900 were incubated in minimum essential
medium (MEM) for 72 h in the presence of 3-fold serial dilutions at 37°C in a humidiﬁed atmosphere
containing 5% CO2. Parasite viability was assessed with the viability marker resazurin after a 3-day drug
exposure time as previously reported (29).
Mouse acute toxicity. In order to determine the no-observed-adverse-effect level (NOAEL), increas-
ing doses of the tested compounds (up to 200 mg/kg of body weight) were injected by the i.p. route
individually into female Swiss mice (21 to 23 g; n  2 per assay of the tested compounds). Treated
animals were inspected for toxic and subtoxic symptoms according to Organization for Economic
Cooperation and Development (OECD) guidelines (33). Forty-eight hours after compound injection, the
NOAEL values were determined as reported previously (31). Biochemical analyses performed 48 h after
compound exposure were performed at the ICTB platform (Fiocruz/RJ) as reported previously (17, 31).
Mouse infection and treatment. For acute T. cruzi infection models, male and female Swiss Webster
mice (18 to 20 g) obtained from the animal facilities of ICTB were housed at a maximum of 7 per cage,
kept in a speciﬁc-pathogen-free (SPF) room at 20°C to 24°C under a 12-h-light/12-h-dark cycle, and
provided with sterilized water and chow ad libitum. The animals were allowed to acclimate for 7 days
before the start of the experiments. Infection was performed by i.p. injection of 104 bloodstream
trypomastigotes (Y strain). Age-matched noninfected mice were maintained under identical conditions
(26). Quinolines were ﬁrst dissolved in DMSO and then freshly diluted with sterile distilled water. The
stock solution of Bz was prepared in sterile distilled water with 3% Tween 80 (Sigma-Aldrich). The animals
were divided into the following groups (n  3 per group): uninfected (noninfected and nontreated),
untreated (infected but treated with the vehicle only), and treated (infected and treated with the
compounds). Therapy was performed through the administration of 5 to 20 mg/kg at parasitemia onset
(5 dpi) and the peak of parasitemia (8 dpi) according to an animal model reported previously (23).
Alternatively, the most promising quinoline derivatives were administered for ﬁve consecutive days,
starting at 5 dpi, using up to 25 mg/kg/day (i.p.) and 100 mg/kg/day Bz (orally [p.o.]). For all assays, only
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mice with positive parasitemia were used in the infected groups. Parasitemia levels in T. cruzi assays were
individually checked by direct microscopic counting of parasites in 5 l of blood, and mortality rates were
checked daily until 30 days posttreatment and expressed as a percentage of cumulative mortality (CM)
as described previously (27).
For T. brucei models, efﬁcacy experiments were performed as previously reported (32), with modi-
ﬁcations to soften the stringency of the mouse model of infection, and in line with the 3R principles for
animal testing (reduce, reﬁne, and replace), the number of mice was reduced in the primary in vivo
screen. Female NMRI mice were infected i.p. with 104 T. b. rhodesiense STIB900 bloodstream trypano-
somes. Experimental groups of two mice were treated with the new test compounds at 40 mg/kg i.p. on
three consecutive days from day 1 to day 3 postinfection (total dose of 120 mg/kg i.p.). A control group
was infected but remained untreated. The tail blood of all mice was checked microscopically for
parasitemia reduction 24 h and 96 h after the last dose. Parasite reduction in mice treated with the
experimental compounds was compared with that in the untreated control mice. Mice were euthanized
at 96 h posttreatment if parasites were still detected in the tail blood. Aparasitemic mice were further
examined twice per week for 30 days, or mice were euthanized after parasitemia relapses were detected.
Mice that remained aparasitemic until day 30 were considered cured. The data from the follow-up
efﬁcacy study for compounds that achieved a parasite reduction of at least 98% in one of the two treated
mice were comparable to those of groups of 4 infected mice treated for four consecutive days with a
higher dosage of 50 mg/kg i.p. (total dose of 200 mg/kg i.p.). Pentamidine was used as a positive drug
control, and it cured mice at 3 4 mg/kg and 4 1 mg/kg i.p.
Statistical analyses. Statistical analyses were performed by analysis of variance (ANOVA) with the
level of signiﬁcance set at a P value of 0.05.
Ethics. All animal procedures performed at Fiocruz were carried out in accordance with the
guidelines established by the Committee of Ethics for the Use of Animals (CEUA LW16/14). All protocols
and procedures using animal models of T. brucei infection were reviewed and approved by the local
veterinary authorities of the Canton Basel-Stadt, Switzerland.
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